Get started
MODERNAMODERNAMODERNA

MODERNA

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

1MRNA trade ideas

Round Top Pattern. Greetings All, Based on the rounding top pattern, I'm bearish on MRNA in the short-term. Target $116, which is also the 61.8% retracement level from the ATH ($189). Happy Trading! Disclaimer. My ideas are for informational purposes only. My ideas do not constitute solicitation, recommendation, endorsement, or offer to buy or sell any securities or other financial instruments. You should not construe any such information or other comments as legal, tax, investment, financial, or other advice. There are risks associated with investing in securities. Investing in stocks, bonds, exchange traded funds, mutual funds, options and money market funds involve risk of loss.  Loss of principal is possible. Please exercise your own due diligence.
NASDAQ:MRNAShort
by chiefwils0n
4
HERCULES portfolio: now it’s better to consist of cashHERCULES’ mid-term trend chart is presented. Also the mid-term trend charts of the stocks that make up the portfolio are presented. ___ Prompt: New traders should take some time and carefully read the post entitled 'You can't beat the market' that is located in my profile. Disclaimer The author of this text is not an investment advisor. The preceding content is intended to be used for informational and educational purposes only. It is not an advice or inducement for the purchase or sale of the products mentioned. Before making any investment based on your own personal circumstances, it is very important to do your own research and analysis and also take independent financial advice from a professional to verify any information provided here.
NASDAQ:MRNAShort
by Gnothisafton
2
MRNA to 250 in MarMRNA could possibly reach as high as 250’s before or after the earnings report on 10 Mar. Not only it may beat the earnings estimate, there are also quite positive news which may lead to explosive growth. First-in-human clinical trial confirms novel HIV vaccine approach developed by IAVI and Scripps Research NEW YORK and LA JOLLA, CA—A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine. … The study sets the stage for additional clinical trials that will seek to refine and extend the approach—with the long-term goal of creating a safe and effective HIV vaccine. As a next step, IAVI and Scripps Research are partnering with the biotechnology company Moderna to develop and test an mRNA-based vaccine that harnesses the approach to produce the same beneficial immune cells. Using mRNA technology could significantly accelerate the pace of HIV vaccine development. … The strategy of targeting naïve B cells with specific properties is called “germline-targeting,” as these young B cells display antibodies encoded by unmutated, or “germline” genes. Researchers believe the approach could also be applied to vaccines for other challenging pathogens such as influenza, dengue, Zika, hepatitis C viruses and malaria.
NASDAQ:MRNALong
by financialSnail88674
6
MRNA: the cup turns out to be a double top?MRNA’s mid-term trend chart is presented. ___ Prompt: New traders should take some time and carefully read the post entitled 'You can't beat the market' that is located in my profile. Disclaimer The author of this text is not an investment advisor. The preceding content is intended to be used for informational and educational purposes only. It is not an advice or inducement for the purchase or sale of the products mentioned. Before making any investment based on your own personal circumstances, it is very important to do your own research and analysis and also take independent financial advice from a professional to verify any information provided here.
NASDAQ:MRNAShort
by Gnothisafton
HERCULES: weekly portfolio course valuationHERCULES’ mid-term trend chart is presented. ___ Prompt: New traders should take some time and carefully read the post entitled 'You can't beat the market' that is located in my profile. Disclaimer The author of this text is not an investment advisor. The preceding content is intended to be used for informational and educational purposes only. It is not an advice or inducement for the purchase or sale of the products mentioned. Before making any investment based on your own personal circumstances, it is very important to do your own research and analysis and also take independent financial advice from a professional to verify any information provided here.
NASDAQ:MRNALong
by Gnothisafton
4
MRNA: a misleading cup with a handle formation?MRNA’s short-, long and mid-term trend charts are presented. ___ Prompt: New traders should take some time and carefully read the post entitled 'You can't beat the market' that is located in my profile. Disclaimer The author of this text is not an investment advisor. The preceding content is intended to be used for informational and educational purposes only. It is not an advice or inducement for the purchase or sale of the products mentioned. Before making any investment based on your own personal circumstances, it is very important to do your own research and analysis and also take independent financial advice from a professional to verify any information provided here.
NASDAQ:MRNA
by Gnothisafton
4